Fetal exposure to isotretinoin - An international problem

被引:28
作者
Garcia-Bournissen, Facundo [3 ]
Tsur, Lilach [1 ,2 ]
Goidstein, Lee H. [1 ,2 ]
Staroselsky, Arthur [3 ]
Avner, Marina [3 ]
Asrar, Farhan [3 ]
Berkovitch, Matitiahu [1 ,2 ]
Strafacec, Gianluca [4 ]
Koren, Gideon [3 ]
De Santis, Marco [4 ]
机构
[1] Assaf Harofeh Med Ctr, Clin Pharmacol Unit, IL-69978 Zerifin, Israel
[2] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
[3] Univ Toronto, Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherisk Program, Toronto, ON, Canada
[4] Univ Cattolica Sacro Cuore, Dept Obstet & Gynecol, Telefono Rosso Teratol Informat Serv, Rome, Italy
关键词
isotretinoin; pregnancy; teratogen information service; prevention programs;
D O I
10.1016/j.reprotox.2007.10.005
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Isotretinoin is a known teratogen. Pregnancy prevention programs aimed at minimizing isotretinoin exposure in pregnancy have been implemented in North America with limited success. Objective: To compare the management of fetal risk of isotretinoin in three countries, including information given to women, implementation of contraceptive methods, and pregnancy outcomes. Methods: Pregnant women exposed to isotretinoin who called teratogen information services (TIS) in Israel, Italy and Canada between July 1998 and October 2006 were interviewed at the time of initial consultation and after the expected day of delivery. Results: Fifty-three pregnant women exposed to isotretinoin contacted the TIS. Only 41 % reported using a birth control method. Just one patient reported using two different forms. Forty-five percent of exposed pregnancies were terminated before delivery and 22% delivered healthy babies. Two babies were born with malformations. Conclusions: Since isotretinoin-exposed pregnancies still occur, there is a need for more effective strategies, which should take into account the cultural differences. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:124 / 128
页数:5
相关论文
共 34 条
[1]   What is the best approach to reducing birth defects associated with isotretinoin? [J].
Abroms, Lorien ;
Maibach, Edward ;
Lyon-Daniel, Katherine ;
Feldman, Steven R. .
PLOS MEDICINE, 2006, 3 (11) :1978-1983
[2]   Patterns and utilization of isotretinoin for acne from 1984 to 2003:: is there need for concern? [J].
Azoulay, Laurent ;
Oraichi, Driss ;
Berard, Anick .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (08) :667-674
[3]  
BENKE PJ, 1984, JAMA-J AM MED ASSOC, P3267
[4]   Isotretinoin, pregnancies, abortions and birth defects:: a population-based perspective [J].
Berard, Anick ;
Azoulay, Laurent ;
Koren, Gideon ;
Blais, Lucie ;
Perreault, Sylvie ;
Oraichi, Driss .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (02) :196-205
[5]  
BOUCHER N, 2006, CAN FAM PHYSICIAN, P338
[6]   Trends in adherence to a revised risk management program designed to isotretinoin-exposed decrease or eliminate pregnancies - Evaluation of the Accutane SMART Program [J].
Brinker, A ;
Kornegay, C ;
Nourjah, P .
ARCHIVES OF DERMATOLOGY, 2005, 141 (05) :563-569
[7]   TERMINATIONS OF PREGNANCY FOR EXPOSURE TO ORAL RETINOIDS IN SOUTH-AUSTRALIA, 1985-1993 [J].
CHAN, A ;
KEANE, RJ ;
HANNA, M ;
ABBOTT, M .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1995, 35 (04) :422-426
[8]   Retinoic acid embryopathy: Case report and review of literature [J].
Coberly, S ;
Lammer, E ;
Alashari, M .
PEDIATRIC PATHOLOGY & LABORATORY MEDICINE, 1996, 16 (05) :823-836
[9]   EPIDEMIOLOGY OF ISOTRETINOIN EXPOSURE DURING PREGNANCY [J].
DAI, WS ;
LABRAICO, JM ;
STERN, RS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 26 (04) :599-606
[10]  
DELA CE, 1984, PEDIATRICS, P428